Opinion|Videos|October 25, 2024

Emerging Trends and Rising Prevalence of mCSPC

Author(s)Joeseph Renzulli, MD, Ganesh V. Raj, MD, PhD, Scott B. Sellinger, MD

Key Takeaways

Improved diagnostic techniques and an aging population contribute to the increasing prevalence of mCSPC.
Earlier detection and personalized therapeutic strategies are becoming more common in mCSPC management.
Advances in imaging and biomarker identification enhance disease characterization and treatment precision.
Understanding molecular and genetic aspects of mCSPC is crucial for developing novel targeted therapies.

SHOW MORE

Panelists discuss how the prevalence of metastatic castration-sensitive prostate cancer (mCSPC) has been increasing, potentially influenced by changes in prostate-specific antigen screening recommendations and rising diagnoses of metastatic hormone-sensitive prostate cancer.

Episodes in this series

EP. 1 Emerging Trends and Rising Prevalence of mCSPC

EP. 1 Emerging Trends and Rising Prevalence of mCSPC

EP. 2 Defining mCSPC: Diagnostic Criteria, Imaging Approaches, and Patient Identification

EP. 2 Defining mCSPC: Diagnostic Criteria, Imaging Approaches, and Patient Identification

EP. 3 Overcoming Unmet Needs in Treating mCSPC: ADT Monotherapy vs Multimodal Approaches

EP. 3 Overcoming Unmet Needs in Treating mCSPC: ADT Monotherapy vs Multimodal Approaches

EP. 4 Managing Biochemical Recurrence in Prostate Cancer: Risk Stratification and Treatment Decisions

EP. 4 Managing Biochemical Recurrence in Prostate Cancer: Risk Stratification and Treatment Decisions

EP. 5 Innovative Treatment Strategies in High-Risk Biochemical Recurrence: Insights From the EMBARK Trial

EP. 5 Innovative Treatment Strategies in High-Risk Biochemical Recurrence: Insights From the EMBARK Trial

EP. 6 Navigating Treatment Options in mCSPC: Choosing the Right Doublet or Triplet Therapy

EP. 6 Navigating Treatment Options in mCSPC: Choosing the Right Doublet or Triplet Therapy

EP. 7 Managing Cognitive and Sexual Health in Prostate Cancer Patients on Hormonal Therapy

EP. 7 Managing Cognitive and Sexual Health in Prostate Cancer Patients on Hormonal Therapy

Video content above is prompted by the following:

What is the prevalence of mCSPC? What trends have emerged in recent years?

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Latest CME

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom

FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent

Mary Dunn, MSN, NP-C, OCN, RN, on advances reshaping advanced prostate cancer care

The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD

Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy